Thomas Amatruda
Overview
Explore the profile of Thomas Amatruda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
2071
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Andtbacka R, Amatruda T, Nemunaitis J, Zager J, Walker J, Chesney J, et al.
EBioMedicine
. 2019 Aug;
47:89-97.
PMID: 31409575
Background: Talimogene laherparepvec (T-VEC) is an intralesionally delivered, modified herpes simplex virus type-1 oncolytic immunotherapy. The biodistribution, shedding, and potential transmission of T-VEC was systematically evaluated during and after completion...
2.
Perez M, Zager J, Amatruda T, Conry R, Ariyan C, Desai A, et al.
Melanoma Manag
. 2019 Aug;
6(2):MMT19.
PMID: 31406563
Aim: Talimogene laherparepvec (T-VEC) is an intralesional treatment for unresectable cutaneous, subcutaneous and nodal melanoma. COSMUS-1 was conducted to examine how T-VEC is used in US clinical practice. Materials &...
3.
Chesney J, Awasthi S, Curti B, Hutchins L, Linette G, Triozzi P, et al.
Melanoma Res
. 2017 Nov;
28(1):44-51.
PMID: 29176501
Talimogene laherparepvec is a genetically modified herpes simplex virus-1-based oncolytic immunotherapy for the local treatment of unresectable cutaneous, subcutaneous, and nodal tumors in patients with melanoma recurrence following surgery. We...
4.
Sperduto P, Jiang W, Brown P, Braunstein S, Sneed P, Wattson D, et al.
Int J Radiat Oncol Biol Phys
. 2017 Oct;
99(4):812-816.
PMID: 29063850
Purpose: To update the Diagnosis-Specific Graded Prognostic Assessment (DS-GPA) for a markedly heterogeneous patient population, patients with melanoma and brain metastases, using a larger, more current cohort, including molecular markers....
5.
Sperduto P, Jiang W, Brown P, Braunstein S, Sneed P, Wattson D, et al.
Int J Radiat Oncol Biol Phys
. 2017 Jul;
98(5):1069-1077.
PMID: 28721890
Purpose: Brain metastases are a common problem in patients with melanoma, but little is known about the effect of gene mutations on survival in these patients. Methods And Materials: We...
6.
Andtbacka R, Agarwala S, Ollila D, Hallmeyer S, Milhem M, Amatruda T, et al.
Head Neck
. 2016 Jul;
38(12):1752-1758.
PMID: 27407058
Background: Cutaneous head and neck melanoma has poor outcomes and limited treatment options. In OPTiM, a phase 3 study in patients with unresectable stage IIIB/IIIC/IV melanoma, intralesional administration of the...
7.
Andtbacka R, Ross M, Puzanov I, Milhem M, Collichio F, Delman K, et al.
Ann Surg Oncol
. 2016 Jun;
23(13):4169-4177.
PMID: 27342831
Purpose: Talimogene laherparepvec (T-VEC) is an oncolytic immunotherapy designed to induce tumor regression of injected lesions through direct lytic effects, and of uninjected lesions through induction of systemic antitumor immunity....
8.
Kaufman H, Amatruda T, Reid T, Gonzalez R, Glaspy J, Whitman E, et al.
J Immunother Cancer
. 2016 Mar;
4:12.
PMID: 26981242
Background: We previously reported that talimogene laherparepvec, an oncolytic herpes virus encoding granulocyte-macrophage colony-stimulating factor (GM-CSF), resulted in an objective response rate of 26 % in patients with advanced melanoma...
9.
Andtbacka R, Kaufman H, Collichio F, Amatruda T, Senzer N, Chesney J, et al.
J Clin Oncol
. 2015 May;
33(25):2780-8.
PMID: 26014293
Purpose: Talimogene laherparepvec (T-VEC) is a herpes simplex virus type 1-derived oncolytic immunotherapy designed to selectively replicate within tumors and produce granulocyte macrophage colony-stimulating factor (GM-CSF) to enhance systemic antitumor...
10.
Kaufman H, Kirkwood J, Hodi F, Agarwala S, Amatruda T, Bines S, et al.
Nat Rev Clin Oncol
. 2013 Aug;
10(10):588-98.
PMID: 23982524
Immunotherapy is associated with durable clinical benefit in patients with melanoma. The goal of this article is to provide evidence-based consensus recommendations for the use of immunotherapy in the clinical...